# Compass Therapeutics (CMPX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/CMPX
## Company Profile
- Ticker: CMPX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, Antibody Drugs, Oncology
## Stock Data
- Close: 2.37 USD
- Market cap: 374582863.2 USD
- Last updated: 2026-08-12
## Business Overview
### Antibody-Based Oncology
Compass Therapeutics develops antibody therapies at the intersection of angiogenesis, tumor immunity and immune suppression. Its portfolio includes bispecific antibodies and immune activators intended to disrupt tumor blood supply while restoring antitumor immune activity.
### Tovecimig
Tovecimig is a DLL4 and VEGF-A bispecific antibody being developed with paclitaxel for second-line biliary tract cancer. The Phase 2/3 program showed statistically significant progression-free-survival improvement and signals of an overall-survival benefit, supporting a planned BLA.
### CTX-8371
CTX-8371 is a PD-1 and PD-L1 bispecific antibody in Phase 1 development for patients whose tumors progressed after checkpoint inhibitors. Early responses in triple-negative breast cancer, non-small cell lung cancer and Hodgkin lymphoma prompted expansion cohorts in those indications.
### CTX-10726 and CTX-471
CTX-10726 combines PD-1 blockade with VEGF-A inhibition and has entered Phase 1 testing in the post-checkpoint setting. CTX-471 is an immune-activating antibody planned for Phase 2 evaluation in tumors expressing NCAM, or CD56.
## Why The Stock Is Moving

As of Aug 12, 2026, CMPX closed up 7.73% at $2.37. No new same-company headline was identified in the current news window.

## Future Catalysts

- Tovecimig meeting with the FDA followed by a planned BLA submission later in 2026.
- CTX-8371 dose-escalation and early expansion-cohort data at ASCO 2026, with additional expansion data expected in the fourth quarter of 2026.
- Initial Phase 1 data for CTX-10726 expected in the fourth quarter of 2026.
- Initiation of a Phase 2 trial of CTX-471 expected in the second half of 2026.

## Recent News
- 2026-08-06 11:30 EST — [Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/CMPX/compass-therapeutics-reports-2026-second-quarter-financial-results-and-provides--7f8ce8b7) — Source: Compass Therapeutics
- 2026-07-17 14:42 EST — [Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026](https://biopharmsignal.com/news/CMPX/compass-therapeutics-announces-tovecimig-data-accepted-for-an-oral-presentation--350ddb60) — Source: Compass Therapeutics
- 2026-05-28 11:30 EST — [Compass Therapeutics to Participate in Upcoming June Investor Events](https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-june-investor-events-1eb21840) — Source: Compass Therapeutics
- 2026-05-21 21:00 EST — [Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-present-promising-phase-1-clinical-data-for-ctx-8371-in--211bb911) — Source: Compass Therapeutics
- 2026-05-12 11:30 EST — [Compass Therapeutics to Participate in Upcoming May Investor Events](https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-may-investor-events-a79d8121) — Source: Compass Therapeutics